Julian Delgado
Family Medicine · Colusa, CANPI 1609826338
Payments from drug & device makers
Across 111 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$286
- Novo Nordisk$238
- Johnson & Johnson$228
- AstraZeneca$213
- Boehringer Ingelheim$142
- Lilly USA, LLC$133
- plus $832 from 19 others
What the payments were for
- Food & beverage$2,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $286 |
| Novo Nordisk | 11 | $238 |
| Johnson & Johnson | 14 | $228 |
| AstraZeneca | 15 | $213 |
| Boehringer Ingelheim | 8 | $142 |
| Lilly USA, LLC | 7 | $133 |
| Exact Sciences | 6 | $121 |
| GSK | 5 | $102 |
| Dexcom, Inc. | 3 | $91 |
| Edwards Lifesciences | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| Cranial Technologies, Inc | 3 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Bayer | 2 | $36 |
| Mylan Specialty L.p. | 2 | $33 |
| Biogen | 1 | $32 |
| Agios Pharmaceuticals, Inc. | 1 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Advanced Respiratory, Inc | 1 | $26 |
| Medtronic | 1 | $24 |
| Amgen | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,071 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $49,833 |
| TrulicityDulaglutide | 30 | $43,533 |
| EliquisApixaban | 48 | $41,939 |
| FarxigaDapagliflozin Propanediol | 28 | $37,642 |
| JardianceEmpagliflozin | 14 | $12,593 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,001 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 140 | $2,868 |
| Levothyroxine Sodium | 127 | $2,348 |
| Carvedilol ErCarvedilol Phosphate | 11 | $2,345 |
| Atorvastatin Calcium | 217 | $2,238 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,023 |
| Omega-3 Acid Ethyl Esters | 38 | $1,953 |
| Irbesartan | 48 | $1,755 |
| Fentanyl | 13 | $1,719 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $238 | $49,83342 claims |
| Lilly USA, LLCTrulicity | $133 | $43,53330 claims |
| AstraZenecaFarxiga | $213 | $37,64228 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $142 | $18,59426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Colusa
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.